Osmotica Pharmaceuticals PLC (NASDAQ:OSMT) Q2 2019 Earnings Conference Call - Final Transcript

Aug 08, 2019 • 04:30 pm ET


Osmotica Pharmaceuticals PLC (NASDAQ:OSMT) Q2 2019 Earnings Conference Call - Final Transcript


Loading Event

Loading Transcript


Good day, ladies and gentlemen, and welcome to the Osmotica Q2 2019 Earnings Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will follow at that time. [Operator Instructions].

I would now like to introduce your host for today's conference call, Ms. Lisa Wilson, Investor Relations of Osmotica. You may begin.

Lisa Wilson

Thank you, operator. Welcome to Osmotica Pharmaceuticals Second Quarter 2019 Business Update Call. This is Lisa Wilson, Investor Relations for Osmotica. With me on today's call are Osmotica's Chief Executive Officer, Brian Markison; Chief Operating Officer, JD Schaub; and Chief Financial Officer, Andrew Einhorn. This afternoon, the company issued a press release detailing financial results for the three months ended June 30, 2019. This press release and a webcast of this call can be accessed through the Investor section of the Osmotica website at osmotica.com.

Before we get started, I would like to remind everyone that any statements made on today's conference call that express a belief, expectation, projection, forecast, anticipation or intent regarding future events and the company's future performance may be considered forward-looking statements as defined by the Private Securities Litigation Reform Act. These forward-looking statements are based on information available to Osmotica's management as of today and involve risks and uncertainties, including those noted in this afternoon's press release and our filings with the SEC. Such forward-looking statements are not guarantees of future performance. Actual results may differ materially from those projected in the forward-looking statements.

Osmotica specifically disclaims any intent or obligation to update these forward-looking statements, except as required by law. The archived webcast of this call will be available for 30 days on our website, osmotica.com. For the benefit of those who may be listening to the replay or archived webcast, this call was held and recorded on August 8, 2019. Since then, Osmotica may have made announcements related to the topics discussed, so please reference the company's most recent press releases and SEC filings.

And with that, I'll turn the call over to Osmotica's CEO, Brian Markison.

Brian A. Markison

Good afternoon, and thank you for joining the call. I'm pleased to report that Osmotica continues to advance its strategy to transform to a specialty pharmaceutical company. First and foremost, we are on track to submit the NDA next month for RVL-1201, our breakthrough product for the treatment of ptosis, more commonly known as droopy eye. The company has completed its assessment of the global potential and outreach to prospective partners begins in earnest this month. Furthermore, we've begun to realign our operating expense base to prepare for commercial introduction possibly as early as Q3 2020. The company's outreach the KOLs, presence at key scientific meetings and publications will begin to take this story come to life. We have already received notifications of acceptance to various publications and live presentations at upcoming medical meetings, which will be the topic of future releases. We believe that RVL-1201 has the potential to improve peripheral field of